Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 8/20 | 0.46 |
| ▸ | HTR2A | P28223 | 7/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6000210 | 0.81 | SLC6A4 (0.56) | RHEBHTR2ASLC6A4KCNH2 | |
| SCHEMBL6000287 | 0.80 | RHEB (0.66) | RHEBHTR2ATRPM8CHEK1SLC6A4 | |
| SCHEMBL5502216 | 0.75 | SLC6A4 (0.42) | HTR2ATRPM8SLC6A4KCNH2 | |
| SCHEMBL5502059 | 0.74 | RHEB (0.48) | RHEB | |
| SCHEMBL6000227 | 0.74 | HTR2A (0.39) | RHEBHTR2ATRPM8SLC6A4KCNH2 | |
| SCHEMBL5503983 | 0.74 | SLC6A4 (0.50) | HTR2ATRPM8SLC6A4KCNH2SOS1 | |
| SCHEMBL5500733 | 0.71 | RHEB (0.47) | RHEBSLC6A4 | |
| SCHEMBL5999729 | 0.70 | AHR (0.49) | RHEBHTR2ATRPM8CHEK1SLC6A4 | |
| SCHEMBL1569795 | 0.67 | TAAR1 (0.61) | HTR2A | |
| SCHEMBL5502115 | 0.67 | SLC6A4 (0.39) | HTR2ATRPM8SLC6A4KCNH2SOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | RHEB 2914/4885HTR2A 7/4885TRPM8 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.